Gateway to Think Tanks
来源类型 | Research Report |
规范类型 | 报告 |
Medicaid Prescriptions for Extended-Release Medications to Treat Opioid Use Disorder | |
Lisa Clemans-Cope; Emma Winiski; Marni Epstein; Luis E. Basurto | |
发表日期 | 2020-04-14 |
出版年 | 2020 |
语种 | 英语 |
概述 | Extended-release prescription medications to treat opioid use disorder (MOUDs) offer long-acting, first-line treatment options for people with opioid use disorder (OUD). These long-acting medications could help retain more people in treatment and help people manage their day-to-day lives successfully—an even more urgent issue in light of the coronavirus pandemic. Three extended-release MOUDs—Vivitrol, Probuphine |
摘要 | Extended-release prescription medications to treat opioid use disorder (MOUDs) offer long-acting, first-line treatment options for people with opioid use disorder (OUD). These long-acting medications could help retain more people in treatment and help people manage their day-to-day lives successfully—an even more urgent issue in light of the coronavirus pandemic. Three extended-release MOUDs—Vivitrol, Probuphine, and Sublocade—have entered the market in recent years, but there is little information about how many Medicaid enrollees receive long-acting MOUD across state Medicaid programs and what the net cost is for Medicaid after adjusting for federal rebates. We analyze Medicaid State Drug Utilization Data from 2011 to 2018 and find the following:
Additionally, in light of the coronavirus pandemic and related barriers to and risks of face-to-face interaction and daily or frequent office visits, health care providers and Medicaid patients on short-acting MOUDs could consider whether extended-release treatments provide more stable medication therapy. This report is part of a larger project, Tracking Medicaid-Covered Prescriptions to Treat Opioid Use Disorder. Click here to learn more. This report was updated April 15, 2020, to remove "per 1,000 Medicaid enrollees" from the title of figure 3 (page 12); the title now correctly describes the total numbers of Sublocade prescriptions across the US in 2018 by state quartile. |
主题 | Health and Health Policy |
URL | https://www.urban.org/research/publication/medicaid-prescriptions-extended-release-medications-treat-opioid-use-disorder |
来源智库 | Urban Institute (United States) |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/480966 |
推荐引用方式 GB/T 7714 | Lisa Clemans-Cope,Emma Winiski,Marni Epstein,et al. Medicaid Prescriptions for Extended-Release Medications to Treat Opioid Use Disorder. 2020. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
medicaid-prescriptio(1517KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。